Background and clinical significance of biomarker-based patient enrichment in non-small-cell lung cancer drug development
Abstract Pharmaceutical companies have adopted biomarker-based enrichment (personalized) strategies to improve research and development productivity. We explored the background in which personalized strategies are adopted and examined whether their adoption is linked to improved efficacy of new drug...
| Main Authors: | , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Nature Portfolio
2024-03-01
|
| Series: | Scientific Reports |
| Online Access: | https://doi.org/10.1038/s41598-024-57556-3 |